Zosano Pharma Corporation (ZSAN)

Trade ZSAN now with
12/23/2019 8:10:31 AM Zosano Pharma Submits 505(b)(2) NDA For Qtrypta To FDA
9/18/2019 8:31:55 AM Zosano Pharma Names Dushyant Pathak As SVP Of Business Development
7/15/2019 6:04:37 AM Zosano Presents Migraine-ACT Scores For Qtrypta Therapy Used Over 6-12 Months
1/16/2019 8:34:20 AM Zosano Appoints Linda Grais To Board
10/16/2018 8:31:41 AM Zosano Pharma Appoints Greg Kitchener CFO
10/3/2018 8:35:25 AM Zosano Pharma Announces Manufacturing And Supply Agreement For M207
9/26/2018 8:31:25 AM Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
9/6/2018 8:38:00 AM Zosano Pharma To Present Phase 3 Safety Study Update For ADAM Technology In Delivery Of Zolmitriptan
7/17/2018 8:37:45 AM Zosano Says Positive Data From Evaluation Of Pharmacokinetics And Skin Tolerability Study For ADAM Technology
5/23/2018 8:36:40 AM Zosano Reports Publication Of Most Bothersome Symptom Data From ZOTRIP Pivotal Study In Headache
5/22/2018 8:35:44 AM Zosano Appoints Steven Elms To Board Of Directors
5/15/2018 4:08:02 PM Zosano Pharma Q1 Loss/share $4.16 Vs. Loss $6.89 Year Ago
4/3/2018 4:17:29 PM Zosano Announces Closing Of Public Offering Of Common Stock
3/29/2018 9:09:03 AM Zosano Pharma Announces Pricing Of Underwritten Public Offering Of 10 Mln Shares At $5.00/shr
3/16/2018 8:32:45 AM Zosano Reaches Enrollment Milestone In M207-ADAM Long-term Safety Study